Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro ...
Winter is Coming8h
Review: The Fury of the Gods brings John Gwynne's Bloodsworn trilogy to a breathtaking but rushed conclusion
The final book of The Bloodsworn trilogy is out. How well did things wrap up for characters like Varg, Orka, and Elvar in the last book of John Gwynne's Norse-inspired epic fantasy saga? The Fury of ...
ceelegalmatters.com16h
The Maximum Fine that the Competition Authority Can Impose Has Increased
From 1 August 2024, the maximum fine that can be imposed by the Hungarian Competition Authority equals 15% of the undertaking ...
Strong Growth Potential for Oruka Therapeutics Driven by Robust Financials and Promising Drug Pipeline
LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating today. Sam Slutsky’s rating ...